Caregen Co.Ltd (214370) - Total Liabilities
Based on the latest financial reports, Caregen Co.Ltd (214370) has total liabilities worth ₩17.10 Billion KRW (≈ $11.59 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Caregen Co.Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how Caregen Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. See Caregen Co.Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Caregen Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Caregen Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sage Therapeutics Inc
NASDAQ:SAGE
|
USA | $54.19 Million |
|
Peet Ltd
AU:PPC
|
Australia | AU$403.77 Million |
|
Echoiq Ltd
AU:EIQ
|
Australia | AU$718.61K |
|
SEALSQ Corp
NASDAQ:LAES
|
USA | $23.89 Million |
|
COOR Service Management AB
ST:COOR
|
Sweden | Skr5.37 Billion |
|
Hubei Kailong Chemical Group Co Ltd
SHE:002783
|
China | CN¥4.54 Billion |
|
SAPPI LTD ADR/1 RC 1
F:SPIA
|
Germany | €3.65 Billion |
|
Fanli Digital Technology Co Ltd
SHG:600228
|
China | CN¥161.42 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Caregen Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 214370 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Caregen Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Caregen Co.Ltd (2015–2024)
The table below shows the annual total liabilities of Caregen Co.Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩17.72 Billion ≈ $12.01 Million |
-11.31% |
| 2023-12-31 | ₩19.98 Billion ≈ $13.54 Million |
+10.43% |
| 2022-12-31 | ₩18.09 Billion ≈ $12.26 Million |
+6.16% |
| 2021-12-31 | ₩17.04 Billion ≈ $11.55 Million |
+49.55% |
| 2020-12-31 | ₩11.40 Billion ≈ $7.72 Million |
-23.20% |
| 2019-12-31 | ₩14.84 Billion ≈ $10.06 Million |
+4.61% |
| 2018-12-31 | ₩14.18 Billion ≈ $9.61 Million |
-6.65% |
| 2017-12-31 | ₩15.19 Billion ≈ $10.30 Million |
+1.14% |
| 2016-12-31 | ₩15.02 Billion ≈ $10.18 Million |
+96.52% |
| 2015-12-31 | ₩7.65 Billion ≈ $5.18 Million |
-- |
About Caregen Co.Ltd
Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG S… Read more